BeiGene: FDA to Review Brukinsa Combo in Relapsed, Refractory Follicular Lymphoma
By Colin Kellaher
BeiGene on Wednesday said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of Brukinsa for certain patients with follicular lymphoma, the most common slow-growing non-Hodgkin lymphoma.
The Beijing biotechnology company said the application covers Brukinsa in combination with obinutuzumab for adults with relapsed or refractor follicular lymphoma after at least two prior lines of therapy.
BeiGene said the FDA has assigned a target action date in the first quarter of 2024, adding that approval would mark the fifth U.S. indication for Brukinsa.
BeiGene reported global Brukinsa sales of $211.4 million for the first quarter of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 12, 2023 07:33 ET (11:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom